Muromachi Chemicals Inc.
Supplementary Financial Presentation Materials
The supplementary materials report increases in revenue and operating income following the transition to a two-segment structure. Both Pharmaceuticals and Chemicals saw revenue growth, while improvements in cost of goods sold and reductions in selling, general and administrative expenses drove overall profit increases. The second-quarter earnings forecast was revised, while the full-year forecast remains unchanged. The company plans to strengthen technical capabilities through initiatives such as establishing a Chemicals Development Center.
Key Figures
- Revenue: 1,861 million yen (Q1, Year-over-Year +4.1%)
- Operating Income: 182 million yen (Year-over-Year +108 million yen)
- Ordinary Income: 191 million yen (Year-over-Year +118 million yen)
- Net Income Attributable to Owners of Parent: 142 million yen (Year-over-Year +84 million yen)
AI要約
Overview
The supplementary materials report that, as the initial results following the transition to a two-segment structure, both the Pharmaceuticals and Chemicals divisions achieved increases in revenue and operating income. Improvements in cost of goods sold and reductions in selling, general and administrative expenses expanded gross profit and operating income. The impact of withdrawing from the health foods business was absorbed, resulting in profitability at the consolidated level. As of the end of the first quarter of the fiscal year ending May 2027, the equity ratio improved by 5.1 percentage points, and total assets declined due to a decrease in current liabilities.
Outlook and Strategy
Following the shift to a two-segment structure, the company expects to maintain revenue growth in both Pharmaceuticals and Chemicals. It will promote strengthening of technical capabilities through the establishment of a Chemicals Development Center and the creation of new products. Although the second-quarter earnings forecast was revised, the full-year forecast remains aligned with the prior outlook. Medium-term priorities include enhancing profitability by expanding imported active pharmaceutical ingredients and securing in-house manufacturing projects.
Muromachi Chemicals Inc.
Company overview · Stock price · Financial data · All IR
